Nexalin Technology invites investors to a webinar discussing its neurostimulation device's clinical data and market progress.
Quiver AI Summary
Nexalin Technology, Inc. is inviting investors to join a webinar on January 23, 2025, at 4:15 p.m. ET, hosted by RedChip Companies. During the event, CEO Mark White will discuss the company's expanding clinical data for its non-invasive deep brain stimulation device and advancements in the new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin's innovative solutions are aimed at treating mental health issues like insomnia, PTSD, and traumatic brain injuries, positioning the company for substantial growth in a market expected to reach $537 billion by 2030. The session will include a live Q&A with White, and registration is available online.
Potential Positives
- Nexalin is hosting an exclusive webinar featuring CEO Mark White, highlighting the company’s growing clinical data and progress on innovative products.
- The company is positioned as an emerging leader in a market projected to reach $537 billion by 2030, focusing on effective treatments for mental health conditions impacting millions.
- Nexalin’s solutions have demonstrated clinically meaningful improvements in treating conditions like insomnia, PTSD, and traumatic brain injuries.
- The approval of the Nexalin Gen-2 device in multiple countries (China, Brazil, Oman) indicates regulatory progress and potential for international market expansion.
Potential Negatives
- Company's reliance on forward-looking statements highlights uncertainties and potential risks that could hinder actual performance, raising concerns for investors.
- Only a few markets have approved Nexalin's Gen-2 device, which may indicate challenges in achieving broader regulatory acceptance and validation for its products.
- The press release emphasizes the emerging nature of Nexalin's technologies, which may imply that they are not yet widely adopted or proven in the market, potentially questioning their viability.
FAQ
What is the date and time for the Nexalin webinar?
The Nexalin webinar is scheduled for January 23, 2025, at 4:15 p.m. ET.
Who will present at the Nexalin webinar?
Nexalin CEO Mark White will present at the webinar, discussing the company’s clinical data and advancements.
How can I register for the Nexalin webinar?
You can register for the Nexalin webinar at https://redchip.zoom.us/webinar/register/WN_5oARuMZLTneaMtsRpZshQQ.
What conditions does Nexalin's technology address?
Nexalin’s technology addresses conditions such as insomnia, PTSD, and traumatic brain injuries, offering innovative treatment solutions.
What is the Gen-3 HALO™ Clarity & Virtual Clinic model?
The Gen-3 HALO™ Clarity & Virtual Clinic model represents Nexalin's next generation of deep brain stimulation devices.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NXL Insider Trading Activity
$NXL insiders have traded $NXL stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NXL stock by insiders over the last 6 months:
- DAVID OWENS (Chief Medical Officer) has made 2 purchases buying 1,500 shares for an estimated $2,045 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NXL Hedge Fund Activity
We have seen 11 institutional investors add shares of $NXL stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RENAISSANCE TECHNOLOGIES LLC added 102,900 shares (+inf%) to their portfolio in Q3 2024, for an estimated $68,829
- MORGAN STANLEY removed 59,805 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $40,003
- CITADEL ADVISORS LLC added 58,185 shares (+inf%) to their portfolio in Q3 2024, for an estimated $38,919
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 42,383 shares (+inf%) to their portfolio in Q3 2024, for an estimated $28,349
- GEODE CAPITAL MANAGEMENT, LLC added 34,635 shares (+78.6%) to their portfolio in Q3 2024, for an estimated $23,167
- VIRTU FINANCIAL LLC added 23,447 shares (+inf%) to their portfolio in Q3 2024, for an estimated $15,683
- TWO SIGMA SECURITIES, LLC added 23,045 shares (+inf%) to their portfolio in Q3 2024, for an estimated $15,414
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) --
Nexalin Technology, Inc.
(the “Company” or “Nexalin”)
(Nasdaq: NXL; NXLIW)
is pleased to invite investors to a webinar today, January 23, 2025, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—conditions that affect millions but have limited effective treatments—positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach $537 billion by 2030. A live Q&A session with White will follow the presentation.
To register for the free webinar, please visit:
https://redchip.zoom.us/webinar/register/WN_5oARuMZLTneaMtsRpZshQQ
.
Questions can be pre-submitted to
NXL@redchip.com
or online during the live event.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at:
https://nexalin.com/
.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website,
www.sec.gov
. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
NXL@redchip.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
